Cyclooxygenase-2 is overexpressed in bladder cancer cells, making it an attractive molecular target for the detection and treatment of cancer. Cyclooxygenase-2 is overexpressed in bladder cancer cells ...

BERLIN -- A Chinese trial that screened advanced urothelial cancer patients for HER2-expression demonstrated a large survival benefit with a novel chemotherapy-free combination in the first-line ...

Concurrent chemoradiotherapy (CRT) for bladder cancer: Practice patterns and outcomes in the general population. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract ...

Aidixi combined with toripalimab significantly improved progression-free and overall survival in HER2-expressing urothelial carcinoma, regardless of cisplatin eligibility or HER2 expression status.

Bladder cancer is a rare form of cancer, with a relatively high recovery rate. Recurrence is still an issue; however, with around half of patients affected. Prognostic tests can help identify patients ...

In a phase 1b-2 trial, neoadjuvant disitamab vedotin plus tislelizumab shows preliminary efficacy and acceptable toxicity in HER2-expressing muscle-invasive bladder cancer -- and may enable ...

Postoperative assessment using urinary tumor DNA (utDNA) to identify potential candidates for repeat transurethral resection of bladder tumor (re-TURBT) in non-muscle invasive bladder cancer (NMIBC): ...

Cyclooxygenase-2 is overexpressed in bladder cancer cells, making it an attractive molecular target for the detection and treatment of cancer. The effects of TKIs on bladder cancer in vivo were ...